Rush Medical College is the medical school of Rush University, located in the Illinois Medical District, about 3 km (2 miles) west of the Loop in Chicago. Offering a full-time Doctor of Medicine program, the school was chartered in 1837, and today is affiliated primarily with Rush University Medical Center, and nearby John H. Stroger Jr. Hospital of Cook County. In 2021, Rush Medical College was ranked 64th among research institutions in the U.S. by U.S. News & World Report.
Anticancer therapies have been increasingly associated with Takotsubo cardiomyopathy (TTC). As prior reports remain fragmented across case studies and drug-specific reviews, this paper offers one of the most comprehensive reviews to date of cancer therapy-associated TTC. While classically triggered by emotional or physical stress, TTC has been increasingly associated with chemotherapy and other cancer-directed therapies. This literature review explores the pathophysiology, clinical features, and evolving evidence linking anticancer agents to TTC, with a focus on cytotoxic cancer therapy, hormonal therapy, targeted treatments, and immune checkpoint inhibitors.We describe the proposed mechanisms of cancer therapy-associated TTC, the diagnostic challenges, particularly in patients with cancer, and the complex management strategies, especially regarding the decision to resume oncologic treatment after TTC recovery.Given the increasing use of cardiotoxic agents, a multidisciplinary approach to cardio-oncology care among patients with suspected TTC is crucial. More research is needed to understand the role of TTC in cardiac dysfunction among patients with cancer, clarify risk stratification methods, and improve outcomes for patients at risk of TTC during cancer treatment.
ABSTRACT:Advanced systemic mastocytosis (AdvSM), a clonal hematologic neoplasm driven predominantly by D816V-mutant KIT, is often characterized by organ damage. Associated hematologic neoplasms (AHNs; usually myeloid) are often present, leading to poor survival. We report on the oral, highly selective, potent KIT D816V inhibitor avapritinib (200 mg once daily, starting dose) with >4 years follow-up from the fully enrolled PATHFINDER study. End points included overall response rate (ORR; primary), duration of response (DOR), progression-free survival (PFS), overall survival (OS), changes in objective biomarkers of disease, and safety (all secondary). Of 107 patients with AdvSM (including 71 [66%] with SM-AHN; overall population median follow-up, 49 months), 83 were response-evaluable. ORR was 73% (95% confidence interval, 63-83). Median DOR was 58 months; PFS, 51 months, and OS, 62 months. Disease progression occurred in 21 of 107 patients (20%), predominantly in SM-AHN and largely driven by the AHN. Reductions in objective biomarkers of disease were observed. Most frequent (≥30% patients) treatment-emergent adverse events (TEAEs; any grade; grade ≥3) were thrombocytopenia (58%; 31%); periorbital edema (57%; 6%), anemia (54%; 33%), peripheral edema (48%; 2%), and diarrhea (36%; 5%). Adverse events of special interest were cognitive effects (34%; 8%) and intracranial bleeds (4%; 2%). Eleven (10%) patients experienced TEAEs leading to death, of which 1 was deemed related to avapritinib by the principal investigator. With 4-year follow-up, patients with AdvSM treated with avapritinib experienced deep and durable responses and a favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as #NCT03580655.
Graph Neural Networks (GNNs) have emerged as a novel paradigm that enables scientists to model complex relational data in medical applications, offering unique advantages over traditional deep learning (DL) approaches for non-Euclidean domains. This paper provides a comprehensive review of current GNN architectures and their healthcare applications, with a focus on functional connectivity analysis, electrical-based diagnostics, and anatomical structure modeling. We analyze the strengths and limitations of spectral and spatial GNN variants, including Graph Convolutional Networks (GCNs), Graph Attention Networks (GATs), and spatio-temporal extensions. Based on our critical assessment of the state-of-the-art innovations, we propose several key directions for medical researchers actively developing GNN technology: (1) Dynamic graph representation learning to capture evolving physiological processes; (2) Multi-modal fusion techniques to integrate heterogeneous biomedical data streams; (3) Uncertainty-aware GNNs for robust clinical decision support; (4) Explainable GNN architectures to enhance interpretability for healthcare practitioners; and (5) Federated GNN frameworks to enable privacy-preserving collaborative learning across institutions. We also introduce a new Temporal Multi-modal Attention Graph Neural Network (TMA-GNN) architecture designed explicitly for longitudinal patient modeling and clinical trial optimization. Our TMA-GNN incorporates multi-head attention mechanisms, temporal edge construction, and a custom loss function to encourage temporal consistency in predictions. We introduce a conceptual framework for the Temporal Multi-modal Attention Graph Neural Network (TMA-GNN), which is designed to support disease progression modeling and clinical trial optimization in neurological disorders. Although the proposed model architecture is technically detailed, this manuscript focuses on the conceptual and methodological design, rather than presenting experimental results. By addressing these proposed research directions, we envision GNNs will play an increasingly pivotal role in precision medicine, disease progression modeling, and treatment personalization.
Patients with rheumatic diseases have unique reproductive health needs. Recent guidelines have been established by various soceities on this topic. However, the education received by women’s health providers pertaining to the recognition and management of common rheumatic diseases in patients of childbearing age is not well-defined. This study aims to assess knowledge gaps, specify aspects of care with greatest uncertainty, and assess current resources used by women’s health providers in the management of their patients with rheumatic disease. An electronic survey was distributed nationally to physicians and allied health professionals who care for reproductive age women. The survey scored participants on their correct responses and confidence ratings in three sections: (1) patients presenting with a new rheumatic disease, (2) contraception in those with a known rheumatic diagnosis, and (3) preconception/antepartum rheumatology medication management. Participants were also asked about resource utilization. Survey questions and scenarios were based on American College of Obstetrics and Gynecology Committee Opinions and the American College of Rheumatology Guidelines for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Data were captured using RedCap© and analyzed using descriptive statistics. The survey was completed by 200 participants with majority being academic obstetricians and gynecologists. Respondents scored the lowest in recognizing new rheumatic disease presentations in peri-and post-partum periods (28.7